Published in Br J Pharmacol on January 01, 2013
Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones. Biochem Pharmacol (2014) 0.87
Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol (2013) 0.84
Antenatal hypoxia induces epigenetic repression of glucocorticoid receptor and promotes ischemic-sensitive phenotype in the developing heart. J Mol Cell Cardiol (2016) 0.76
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology (2016) 0.76
PR65A phosphorylation regulates PP2A complex signaling. PLoS One (2014) 0.75
Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nat Commun (2017) 0.75
The advantageous role of annexin A1 in cardiovascular disease. Cell Adh Migr (2016) 0.75
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol (2010) 13.76
Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev (2008) 5.52
Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature (1979) 4.41
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci (1994) 2.71
Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev (2006) 2.57
Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J (2002) 2.13
Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol (2010) 1.98
Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol (2005) 1.97
Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat Med (1996) 1.96
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood (2005) 1.62
Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood (2003) 1.60
Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol (2009) 1.39
Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum (2004) 1.39
Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol (2001) 1.35
Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther (2010) 1.29
Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett (2006) 1.29
Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem Cell Biol (1998) 1.26
FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J (2010) 1.23
Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation (2007) 1.17
Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. FASEB J (2001) 1.16
Postconditioning--A new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol (2005) 1.14
Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. FASEB J (2004) 1.05
Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol (2009) 1.00
Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol (2009) 1.00
Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J (2000) 1.00
The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal (2007) 0.99
Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury? Trends Pharmacol Sci (2010) 0.97
A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther (2008) 0.95
Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination. Biochim Biophys Acta (2008) 0.93
Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol (2007) 0.91
Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol (2002) 0.88
Annexin-1 peptide Anx-1(2-26) protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia. Br J Pharmacol (2005) 0.84
Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm (2006) 0.83
Sodium nitroprusside protects adult rat cardiac myocytes from cellular injury induced by simulated ischemia: role for a non-cGMP-dependent mechanism of nitric oxide protection. J Cardiovasc Pharmacol (2006) 0.83
Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro. Eur J Pharmacol (2003) 0.83
Postconditioning improves postischemic cardiac dysfunction independently of norepinephrine overflow after reperfusion in rat hearts: comparison with preconditioning. J Cardiovasc Pharmacol (2010) 0.82
Reduced L-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury. J Cell Biochem (2009) 0.78
[Ischemic postconditioning protects hypertrophic myocardium by ERK1/2 signaling pathway: experiment with mice]. Zhonghua Yi Xue Za Zhi (2009) 0.77
Annexin 1 and melanocortin peptide therapy for protection against ischaemic-reperfusion damage in the heart. ScientificWorldJournal (2006) 0.77
Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol (2008) 5.71
Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest (2004) 4.97
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension (2003) 3.29
Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med (2003) 2.96
Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr (2013) 2.83
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol (2009) 2.68
Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol (2011) 2.57
Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry (2008) 2.43
Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol (2010) 2.37
NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat Methods (2011) 2.29
Oxidation of myofibrillar proteins in human heart failure. J Am Coll Cardiol (2011) 2.13
Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens (2007) 2.09
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis (2012) 2.06
Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation (2009) 2.02
High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 2.00
The effect of successful heart transplant treatment of heart failure on central sleep apnea. Chest (2003) 1.98
Cardiac complications of thoracic irradiation. J Am Coll Cardiol (2013) 1.80
Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension (2006) 1.77
Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail (2012) 1.76
Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol (2011) 1.72
Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol (2012) 1.70
Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail (2011) 1.60
Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy. Circ Heart Fail (2014) 1.58
What is the role of leukocyte depletion in cardiac surgery? Heart Lung Circ (2007) 1.48
Impaired pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity. Chest (2008) 1.46
Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci (2008) 1.44
Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens (2005) 1.44
Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm (2013) 1.44
A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res (2012) 1.43
Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure. Eur Heart J (2005) 1.43
Myocardial ischemia-reperfusion injury, antioxidant enzyme systems, and selenium: a review. Curr Med Chem (2007) 1.42
Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol (2006) 1.42
Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol (2004) 1.41
Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum (2004) 1.39
Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation (2003) 1.38
Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol (2007) 1.29
Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res (2014) 1.29
Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol (2006) 1.27
Post cardiac arrest syndrome: a review of therapeutic strategies. Circulation (2011) 1.26
Hospital characteristics are associated with patient outcomes following out-of-hospital cardiac arrest. Heart (2011) 1.25
Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum (2003) 1.24
Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum (2011) 1.24
Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation (2004) 1.23
Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. J Mol Cell Cardiol (2011) 1.22
Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. J Mol Cell Cardiol (2011) 1.20
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther (2006) 1.19
Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol (2011) 1.19
Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson (2012) 1.18
Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett (2006) 1.17
Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure. Biochem Biophys Res Commun (2002) 1.17
Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat Rev Rheumatol (2011) 1.16
Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. Anesthesiology (2008) 1.15
Relation between QT interval variability and cardiac sympathetic activity in hypertension. Am J Physiol Heart Circ Physiol (2011) 1.15
Advanced glycation end products are direct modulators of β-cell function. Diabetes (2011) 1.14
Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens (2010) 1.12
Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol (2010) 1.11
Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum (2004) 1.10
Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genomics (2011) 1.10
Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol (2006) 1.10
Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol (2010) 1.09
Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors (2003) 1.09
Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res (2007) 1.08
Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis Rheum (2010) 1.08
Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta (2008) 1.06
Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets (2007) 1.06
Evidence for increased atrial sympathetic innervation in persistent human atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.05
Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol (2008) 1.05
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation (2007) 1.05
Diminished NADPH transhydrogenase activity and mitochondrial redox regulation in human failing myocardium. Biochim Biophys Acta (2010) 1.04
Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. J Physiol (2011) 1.03
Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther (2013) 1.03
Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res (2003) 1.03
Raised sympathetic nerve activity in heart failure and central sleep apnea is due to heart failure severity. Circulation (2003) 1.02
Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum (2004) 1.01
Usefulness of cooling and coronary catheterization to improve survival in out-of-hospital cardiac arrest. Am J Cardiol (2010) 1.01
Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol (2009) 1.00
Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension. Hum Mutat (2009) 1.00
Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes (2010) 1.00
Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol (2004) 0.99
The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal (2007) 0.99
Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med (2011) 0.99
Impact of sleep apnea on sympathetic nervous system activity in heart failure. Chest (2003) 0.99
TNF regulates leukocyte-endothelial cell interactions and microvascular dysfunction during immune complex-mediated inflammation. Br J Pharmacol (2005) 0.98
Reactive oxygen species and insulin-resistant cardiomyopathy. Clin Exp Pharmacol Physiol (2009) 0.98
CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail (2011) 0.97
Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med (2013) 0.97
High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy. Nutrition (2009) 0.96
Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress. Hypertension (2010) 0.96
Targeting the side effects of steroid therapy in autoimmune diseases: the role of GILZ. Discov Med (2012) 0.95
Percutaneous mitral annular reduction provides continued benefit in an ovine model of dilated cardiomyopathy. Circulation (2004) 0.95
Increased CD45RA+ FoxP3(low) regulatory T cells with impaired suppressive function in patients with systemic lupus erythematosus. PLoS One (2012) 0.95